NanoViricides, Inc. (NYSE American: NNVC) announced that it will present at NIBA’s 152nd Investment Conference in Fort Lauderdale on March 12, where President and Executive Chairman Anil R. Diwan will outline progress on the company’s broad-spectrum antiviral platform. The company also reported that manufacturing of its NV-387 Oral Gummies drug product has been completed in preparation for patient dosing once clinical sites are ready, as the therapy advances toward a Phase II trial for monkeypox in the Democratic Republic of Congo following a successful Phase I safety study in healthy volunteers.
NV-387 is a unique broad-spectrum antiviral drug candidate that targets multiple viral infections, including RSV, COVID-19, Long COVID, influenza, monkeypox, smallpox, and measles. The company has successfully completed a Phase I human clinical trial in healthy volunteers with no reported adverse events, and is now focused on advancing NV-387 into Phase II human clinical trials. The completion of the oral gummies manufacturing marks a critical milestone, enabling patient dosing in the upcoming Phase II study for monkeypox.
According to the company, NV-387 has shown effectiveness in animal models for monkeypox, smallpox, and measles, underscoring its potential as a broad-spectrum antiviral therapy. The Phase II trial in the Democratic Republic of Congo is designed to evaluate the drug's efficacy in treating monkeypox, a disease that has posed significant public health challenges in the region. NanoViricides’ presentation at the NIBA Investment Conference will provide investors and analysts with an update on the company’s pipeline and strategic direction.
For more information on the press release, visit https://ibn.fm/AILOVA. To stay updated on the latest news from NanoViricides, visit the company’s newsroom at https://ibn.fm/NNVC.
NanoViricides is a clinical-stage company specializing in creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, represents a novel approach to treating a wide range of viral infections. The company’s other advanced drug candidate, NV-HHV-1, targets herpesvirus infections, including HSV-1, HSV-2, VZV shingles, and chickenpox. However, the company cannot project an exact date for filing an IND for any of its drugs due to dependence on external collaborators and consultants.
The completion of NV-387 Oral Gummies manufacturing is a significant step forward for NanoViricides as it prepares to initiate patient dosing. The company’s participation in the NIBA Investment Conference highlights its commitment to engaging with the investment community and advancing its antiviral platform. As NV-387 moves into Phase II trials, the outcomes could have important implications for the treatment of monkeypox and other viral diseases, positioning NanoViricides as a key player in the antiviral therapeutics space.
